Pembrolizumab (Keytruda)

DRUG4 trials

Conditions

Advanced CancerB-cell Lymphoma, AdultMetastatic Breast CarcinomaMetastatic Colorectal CancerMetastatic Endocrine Tumors/ Neuroendocrine TumorsMetastatic Ovarian CancerMetastatic Pancreatic CancerNSCLC

Phase 1

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

CompletedNCT03562871

IO BiotechNSCLC

Start: 2018-08-22End: 2022-04-12Updated: 2022-04-21

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

CompletedNCT03922204

Merus N.V.Advanced Cancer, B-cell Lymphoma, Adult, Solid Tumor, Adult

Start: 2019-05-08End: 2024-11-07Updated: 2024-12-11

Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study

CompletedNCT04262089

University Medical Center GroningenUterine Cancer

Start: 2020-11-01End: 2023-11-01Updated: 2023-12-05

Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

RecruitingNCT01174121

National Cancer Institute (NCI)Metastatic Breast Carcinoma, Metastatic Colorectal Cancer, Metastatic Endocrine Tumors/ Neuroendocrine Tumors +2

Start: 2010-08-26End: 2029-12-27Target: 332Updated: 2026-09-16

2025-04-0125 citations

Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study.

2024-09-0313 citations

Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.

Journal of Clinical Oncology2024-06-014 citations

Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer: An update on recurrence-free survival and correlative biomarkers.

Journal of Clinical Oncology2024-06-01

Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes

Journal for ImmunoTherapy of Cancer2024-05-0124 citations

1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers

Regular and Young Investigator Award Abstracts2023-10-31

Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes

Journal of Clinical Oncology2022-02-01163 citations

184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers

Regular and Young Investigator Award Abstracts2021-11-01

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Journal for ImmunoTherapy of Cancer2021-10-0161 citations

814 MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that that does not show signs of peripheral toxicity

2020-11-013 citations

820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells

2020-11-011 citations

Abstract OT1-01-03: Adoptive cell transfer (ACT) using tumor infiltrating lymphocytes to target neoantigens in patients with metastatic breast cancer

Cancer Research2016-02-151 citations

Pembrolizumab (Keytruda)

Sponsors

Conditions

Phase 1

Phase 2

Related Papers